Sionna Therapeutics (NASDAQ:SION) Shares Down 4.7% – Here’s Why

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) fell 4.7% during trading on Monday . The stock traded as low as $33.39 and last traded at $33.6980. 63,269 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 345,553 shares. The stock had previously closed at $35.37.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Guggenheim increased their price target on Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Freedom Capital lowered Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Citizens Jmp reissued a “market outperform” rating and set a $63.00 price target on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. Finally, Wedbush assumed coverage on Sionna Therapeutics in a research note on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $53.22.

Sionna Therapeutics Trading Down 6.9%

The firm has a market capitalization of $1.49 billion, a PE ratio of -17.03 and a beta of 1.30. The firm has a 50-day moving average of $40.47 and a two-hundred day moving average of $39.89.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.08). Equities research analysts expect that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Sionna Therapeutics

In related news, Director Peter A. Thompson sold 235,863 shares of Sionna Therapeutics stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director owned 3,247,025 shares in the company, valued at approximately $144,947,196. The trade was a 6.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director owned 3,247,025 shares in the company, valued at $144,947,196. The trade was a 6.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,717,962 shares of company stock worth $77,571,889 in the last 90 days. Company insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Viking Global Investors LP lifted its holdings in shares of Sionna Therapeutics by 8.2% during the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after acquiring an additional 242,427 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of Sionna Therapeutics by 30.1% during the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after acquiring an additional 335,942 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Sionna Therapeutics by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after acquiring an additional 41,797 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Sionna Therapeutics by 30.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 831,373 shares of the company’s stock worth $34,203,000 after buying an additional 193,613 shares in the last quarter. Finally, State Street Corp lifted its holdings in Sionna Therapeutics by 188.7% in the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after buying an additional 453,196 shares in the last quarter.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.